Introduction
IVF/ET: averaging at about 30% live births 30% live births per treatment cycle Embryo transfer is an independent factor affecting the outcome of the treatment
The determinants of success of embryo transfer involve the quality of embryo(s) and uterine receptivity, the quality of the intrauterine environment Uterine contractions Uterine contractions constitute one of and the most fundamental components of uterine receptivity important role in embryo implantation Excessive uterine contractions might expel embryos from the uterus Up to date, treatment strategies to reduce uterine reduce uterine contractions contractions before embryo transfer such as the use of beta agonists or non beta agonists or non--steroid anti steroid anti--inflammatory inflammatory drugs drugs have not been shown to provide sufficient benefit Oxytocin Oxytocin and vasopressin V1A antagonists and vasopressin V1A antagonists represent a novel class of drugs developed for patients experiencing threatened premature birth threatened premature birth.
decrease intrauterine production of PGF2a PGF2a reduction of uterine contractions and improvement of uterine blood supply potentially beneficial for embryo implantation. Oxytocin evokes the calcium influx through receptorcoupled calcium channels.
Braileanu et al. (2001) : vasopressin acting through V1A receptors also increases phospholipase C activity
In the uterus, oxytocin remains closely associated with another strong uterotonin, PGF2a PGF2a
In endometrial stromal and glandular cells, oxytocin enhances the secretion of PGF2a and the expression of PGF2a receptor
Oxytocin is locally synthesized in the endometrium and in fetal membranes where it stimulates uterine contractions through action on its own receptors and by increasing PGF2a synthesis In the animal model, the administration of oxytocin stimulates uterine PGF2a expression reduction in endometrial blood supply reduced embryonic survival rate Synthesis of oxytocin is strongly influenced by oestradiol oestradiol Oxytocin and vasopressin plasma concentrations increase during the follicular phase increase during the follicular phase, reaching the maximum around the time of ovulation while they decrease during the luteal phase Oxytocin mRNA in the endometrium follows a similar pattern and also reaches its maximum in the midcycle phase A relative increase in oestradiol concentrations stimulates the synthesis of oxytocin receptors in the myometrium before labour Kimura et al. (1996) : a 300-fold increase in the production of OTR mRNA in pregnant myometrium near term.
Expression of vasopressin V1A receptors V1A receptors and concentrations of vasopressin do not seem to be affected by steroids and are not altered in pregnancy not altered in pregnancy Both oxytocin and vasopressin are involved in induction and maintenance of uterine contractions during labour
Similarities between oxytocin, vasopressin and their receptors may explain cross reactivity cross reactivity of oxytocin to V1A receptors.
It has been shown that oxytocin may still exert its actions even when OTR are blocked, through action upon the V1A receptors Treatment cycles induce an abundant increase in abundant increase in oestradiol oestradiol concentrations (about 10-20 nmol/l) at the end of ovarian stimulation as compared with less then 2 nmol/l before the ovulation in the natural cycle Supraphysiological concentrations of oestradiol induce local (endometrial) production of induce local (endometrial) production of oxytocin oxytocin formation of oxytocin receptors, and -indirectlyformation/ release of PGF2a similar to the prelabour status.
It has been shown that uterine contractile uterine contractile activity in IVF cycles IVF cycles is increased by approximately 6 6--fold fold when measured before embryo transfer as compared with the situation before ovulation in the natural cycle
Uterine contractions in treatment cycles
Uterine contractions play an important role in human reproduction rapid and directed sperm transport and high fundal embryo implantation
In IVF/ET treatments, a progressive decrease in uterine contractions is observed after the egg collection, reaching nearly a quiescent status at the time of blastocyst blastocyst transfer transfer (5-6 days after egg collection)
Such a decrease in contractile activity is thought to further augment the higher implantation rates achieved with blastocyst transfers However, the majority of embryos are still transferred on day 2 or 3 after fertilization, during periods of noticeable uterine contractile activity uterine contractile activity.
The embryo transfer procedure itself is expected to increase the local oxytocin and prostaglandins release Any additional manipulation of the vagina or cervix, such as the use of a tenaculum, provides an additional stimulus for oxytocin/prostaglandin release increases in uterine contractions Mansour et al. : in more than half of patients having mock embryo transfer with methylene blue dye, the dye was seen to be transported into the vagina after the procedure It was also demonstrated that less then 50% of less then 50% of transferred embryos transferred embryos remained in the uterus 1 h after transfer and about 15% 15% of embryos could be found in the vagina after embryo transfer vagina after embryo transfer Considering the above: uterine contractile activity at the time of embryo transfer and especially fundocervical contractions expel embryos from the uterus Fanchin et al. (1998) : about 30% of patients undergoing ET have pronounced uterine contractions.
In that group, success rates of IVF/ET treatment were up to 3 3--fold less fold less compared with the population of patients with 'silent' uteri (16% versus 53% of clinical pregnancies).
That could imply that pharmacological inhibition of increased contractions at the time of embryo transfer could be an attractive target for potential treatment Oxytocin and vasopressin V1A receptors as a novel target in fertility treatments Inhibition of oxytocin and vasopressin V1A receptors improve uterine receptivity by decreasing uterine contractions, interfering with PGF2a/oxytocin systems and possibly improving endometrial perfusion Selective blockade of oxytocin receptors directly halts contractions and decreases PGF2a release in human uterine smooth muscle cells Blocking both vasopressin V1A receptors and OTR may be an optimal optimal approach as oxytocin exerts a relatively strong effect on V1A receptors Currently, only atosiban atosiban, which is a combined oxytocin/ vasopressin V1A antagonist, is registered for human use
Only two other antagonists, the peptidyl, long-acting selective oxytocin antagonist barusiban (FE200440) and the non-peptidyl, orally active, mainly V1A vasopressin antagonist relcovaptan (SR49059) have reached the level of clinical trials.
Other drugs or drug candidates of that group are either not progressing in clinical research or at far earlier stages of development.
Atosiban and barusiban
Atosiban: for threatened premature birth Although it is commonly said to be an 'oxytocin antagonist', its affinity to vasopressin V1A receptors is higher than to oxytocin receptors (4.7 nmol/l versus 397 nmol/l, respectively) Barusiban is a new-generation, peptidyl, OTR-specific antagonist. 300-fold more selective for the human oxytocin receptors than the vasopressin V1A receptors Its plasma half-life varies between 2.2 and 2.8 h In preclinical studies: potency, longer duration of action and reversibility as compared with atosiban In monkeys, it was effective in maintaining low intrauterine pressure near the end of pregnancy, suppressing oxytocin induced premature contractions and preventing early delivery However, in a second-phase clinical trial of women experiencing premature labour, it was not shown not shown to be of satisfactory clinical effectiveness In mice, barusiban was confirmed to support embryo implantation (Figure 1 ).
The original concept of the novel application of atosiban in embryo transfer recipients was first developed in 2004.
before considering the clinical application it was decided to verify its embryotoxic embryotoxic potential potential.
The preclinical study involved the application of two embryotoxicity techniques : Both failed to detect an embryotoxic effect of atosiban in concentrations up to 50-fold therapeutic blood concentrations.
Tests performed on human spermatozoa also failed to show an adverse influence.
The very first case of clinical application of atosiban prior to embryo transfer was published in 2007 a 42-year-old patient who had previously undergone 8 embryo transfers involving a total number of 12 goodquality embryos. Atosiban was administered in intravenous infusion lasting 3 h as per license conditions As its plasma steady state is reached within the first hour of infusion embryo transfer was carried out 60 min from the start of the drug administration. uterine contractions decreased from 11 contractions per 4 min to 7 contractions per 4 min and decrease in their amplitude (Figure 2 ). Therapeutic success (healthy twins delivered 8 months later) encouraged further investigations.
To verify its influence on uterine contractions, a multicentre, randomized, placebo-controlled trial has recently been performed on egg donors After ovarian stimulation and egg collection, the participants started luteal support (micronized progesterone) and had a mock embryo transfer (introduction of an empty embryo transfer catheter into the uterus, mimicking regular embryo transfer).
The study compared the uterine contractions between patients receiving placebo and those receiving infusions of atosiban or barusiban.
